{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(8)"],"submitter":["Chang HC"],"pubmed_abstract":["<h4>Background</h4>This study investigated whether initial SGLT2 (sodium-glucose cotransporter 2) inhibitor-based treatment is superior to metformin-based regimens as a primary prevention strategy among low-risk patients with diabetes.<h4>Methods and results</h4>In this nationwide cohort study, a total of 38 496 patients with diabetes with low cardiovascular risk were identified (age 62.0±11.6 years, men 50%) from January 1 to December 31, 2016. Patients receiving SGLT2 inhibitors-based and metformin-based regimens were 1:2 matched by propensity score. Study outcomes included all-cause mortality, cardiovascular death, hospitalization for heart failure, stroke, and progression to end-stage renal disease. Compared with 1928 patients receiving metformin-based regimens, 964 patients receiving "],"journal":["Journal of the American Heart Association"],"pagination":["e032397"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11262491"],"repository":["biostudies-literature"],"pubmed_title":["Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study."],"pmcid":["PMC11262491"],"pubmed_authors":["Chien KL","Kuo TT","Chang HY","Hung CL","Chen YY","Lin YJ","Chung FP","Chang HC"],"additional_accession":[]},"is_claimable":false,"name":"Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study.","description":"<h4>Background</h4>This study investigated whether initial SGLT2 (sodium-glucose cotransporter 2) inhibitor-based treatment is superior to metformin-based regimens as a primary prevention strategy among low-risk patients with diabetes.<h4>Methods and results</h4>In this nationwide cohort study, a total of 38 496 patients with diabetes with low cardiovascular risk were identified (age 62.0±11.6 years, men 50%) from January 1 to December 31, 2016. Patients receiving SGLT2 inhibitors-based and metformin-based regimens were 1:2 matched by propensity score. Study outcomes included all-cause mortality, cardiovascular death, hospitalization for heart failure, stroke, and progression to end-stage renal disease. Compared with 1928 patients receiving metformin-based regimens, 964 patients receiving ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2025-04-04T14:46:08.752Z","creation":"2025-04-04T14:46:08.752Z"},"accession":"S-EPMC11262491","cross_references":{"pubmed":["38591334"],"doi":["10.1161/JAHA.123.032397"]}}